Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib Combined With Tislelizumab and HAIC in Advanced CRLM
NCT05435313Phase 2Active, not recruiting
- Sponsor
- Fudan University
- Start
- Jul 2022
- Primary completion
- Jan 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of fruquintinib in colorectal cancer (CRC), sponsored by Fudan University. Started Jul 2022; status: active, not recruiting.
02
Drugs
fruquintinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05435313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05435313.